文献速递泌尿生殖与妇科肿瘤放疗

高危/中危前列腺癌HDR与LDR近距离放疗联合外照射随机对照疗效

A Randomized Comparison of High-Dose-Rate and Low-Dose-Rate Prostate Brachytherapy Combined With External Beam Radiation Therapy for Unfavorable Prostate Cancer: Efficacy Results After Median Follow-up of 74 Months.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-04-03

单中心随机试验纳入195例不良局部前列腺癌患者,随机接受盆腔外照射联合HDR(15 Gy)或LDR(110 Gy)近距离放疗,中位随访74个月。结果显示两组4年PSA≤0.2比例、8年bPFS均无显著差异,证实近距离放疗剂量递增疗效优异。

要点

  • HDR组与LDR组8年bPFS分别为86%和85%,无显著差异。

核心结论

  • 在不良局部前列腺癌中,LDR与HDR近距离放疗推量在5年和8年bPFS上无差异,并证实近距离放疗剂量递增疗效优异。

研究设计与样本

  • 患者中42%为中危、58%为高危,中位年龄71岁,中位PSA 11.6 ng/mL,76%接受雄激素剥夺治疗。
  • 外照射剂量46 Gy/23次,68%采用IMRT或VMAT,32%采用3D-CRT。
  • HDR方案为15 Gy,LDR方案为110 Gy。
  • 中位随访74个月(范围43-116个月)。

主要发现

  • 8年bPFS(nadir+2)HDR组86% vs LDR组85%。

关键数值与推荐

  • 治愈定义为4年时PSA≤0.2 ng/mL。
  • 生化失败无进展生存(bFFS)和总生存采用Kaplan-Meier法计算。
  • 所有失败均通过影像学(CT、骨扫描和/或PSMA-PET,PET不可用时±活检)调查。

临床怎么用

  • 对于不良局部前列腺癌,盆腔外照射联合HDR或LDR近距离放疗推量均可作为剂量递增策略。
  • HDR 15 Gy与LDR 110 Gy推量在5年和8年bPFS上未见差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This single-center randomized trial compared health-related Quality of Life for men with unfavorable localized prostate cancer treated with combined pelvic external beam radiation therapy (EBRT) and prostate brachytherapy, randomly assigned to high-dose rate (HDR) or low-dose rate (LDR). We now report efficacy outcomes with a minimum 5-year follow-up. MATERIALS AND METHODS: Consenting patients receiving pelvic EBRT combined with prostate brachytherapy were randomized to either LDR (110 Gy) or HDR (15 Gy). Androgen deprivation was used in 76% of patients. EBRT delivered 46 Gy/23 using intensity modulated radiation therapy or volumetric-modulated arc therapy (68%) or 3-dimensional conformal radiotherapy (32%). Follow-up up was 1, 3, and 6 months, then every 6 months to 3 years, and then annually. Prostate-specific antigen (PSA) ≤0.2 ng/mL at 4 years defined cure. Biochemical failure-free survival (bFFS) and overall survival were calculated by Kaplan-Meier methods. All failures were investigated by imaging (computed tomography, bone scan, and/or Prostate Specific Membrane Antigen- Positron Emission Tomography (PET) ± biopsy if PET was not available. RESULTS: From January 2014 to December 2019, 195 men (42% intermediate risk/58% high risk) were randomly assigned: 108 to HDR and 87 to LDR. The median age was 71 years. Median PSA was 11.6 ng/mL (mean, 27.0 ng/mL). Median follow-up was 74 months (43-116 m). The median PSA nadirs were 0.07 and 0.08 in HDR and LDR (P = .16), and time to nadir was 13.8 and 14.1 months, respectively (P = .87). Four-year PSA ≤0.2 was maintained in 81% and 83% of HDR and LDR (P = .91). Eight-year bPFS (nadir + 2) was 86% and 85%, respectively. Eighteen of 22 biochemical failures have been identified; 3 are isolated local failures, whereas 14 are distant failures (isolated 11; 3 combined). CONCLUSIONS: In this small, randomized comparison, efficacy analysis shows no difference between LDR and HDR boost in bPFS at 5 and 8 years and confirms the excellent efficacy of dose escalation using prostate brachytherapy as documented in Ascende-RT for unfavorable localized prostate cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Crook J, Cheng JC, Arbour G, et al. A Randomized Comparison of High-Dose-Rate and Low-Dose-Rate Prostate Brachytherapy Combined With External Beam Radiation Therapy for Unfavorable Prostate Cancer: Efficacy Results After Median Follow-up of 74 Months. Int J Radiat Oncol Biol Phys. 2025. PMID: 40187573. doi:10.1016/j.ijrobp.2025.03.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。